Wave Life Sci Ord Sh (WVE) 34.32 $WVE WAVE Life
Post# of 273322
Posted On: 09/24/2016 3:07:15 AM
Wave Life Sci Ord Sh (WVE) 34.32 $WVE
WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
BusinessWire - Wed Sep 14, 6:30AM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:00 A.M. ET in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon Aug 15, 3:10PM CDT
--Current financial position supports continued pipeline progression, six clinical programs by 2018 and operations into 2019
WVE: 34.32 (+0.71)
Medical Stocks' Earnings to Watch Next Week: TECH, WVE, EARS
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:21AM CDT
How will medical stocks Bio-Techne, WAVE Life Sciences, and Auris perform this earnings season?
WVE: 34.32 (+0.71), EARS: 1.71 (-0.05), TECH: 108.34 (-1.17)
WAVE Life Sciences (WVE) in Focus: Stock Up 6.1% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:35AM CDT
WAVE Life Sciences Ltd. (WVE) was a big mover last session, as the company saw its shares rise over 6% on the day.
WVE: 34.32 (+0.71), ANIP: 66.64 (-0.17)
WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington's Disease
BusinessWire - Tue Jun 21, 6:00AM CDT
--On track to file investigational new drug (IND) application in late 2016
WVE: 34.32 (+0.71)
WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 6:30AM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 3:00 PM Eastern Time on Wednesday, June 8, 2016 in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 16, 3:30PM CDT
--Entered collaboration with Pfizer to develop genetically targeted therapies for the treatment of metabolic diseases
WVE: 34.32 (+0.71)
WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy
BusinessWire - Mon May 09, 7:00AM CDT
--Preclinical data demonstrates 25-fold enhanced exon-skipping efficiency and broader distribution, including to heart and diaphragm, compared to other exon-skipping therapies
WVE: 34.32 (+0.71)
WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
BusinessWire - Thu May 05, 6:02AM CDT
WAVE Life Sciences Ltd. (NASDAQ:WVE) today announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer's hepatic targeting technology for enhanced delivery to the liver.
WVE: 34.32 (+0.71), PFE: 34.26 (+0.11)
WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference
BusinessWire - Fri Apr 29, 6:30PM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Deutsche Bank 41st Annual Health Care Conference at 3:30 PM EDT on Wednesday, May 4, 2016 in Boston, Mass.
WVE: 34.32 (+0.71), DB: 12.75 (-0.25)
WAVE Life Sciences to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Wed Feb 03, 6:30AM CST
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on advancing potential best-in-class stereopure nucleic acid therapies, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018
BusinessWire - Fri Jan 29, 6:30AM CST
--Over 20 stereopure antisense, exon skipping, and RNAi programs in early discovery and development across multiple therapeutic areas that have the potential to be best-in-class
WVE: 34.32 (+0.71)
WAVE Life Sciences prices IPO at USD16.00 per share
M2 - Wed Nov 11, 7:29AM CST
Biopharmaceutical company WAVE Life Sciences Ltd (NASDAQ: WVE) announced on Wednesday that it has priced its initial public offering (IPO) at a price to the public of USD16.00 per share for its offering 6,375,000 ordinary shares.
WVE: 34.32 (+0.71)
WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
BusinessWire - Wed Sep 14, 6:30AM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:00 A.M. ET in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon Aug 15, 3:10PM CDT
--Current financial position supports continued pipeline progression, six clinical programs by 2018 and operations into 2019
WVE: 34.32 (+0.71)
Medical Stocks' Earnings to Watch Next Week: TECH, WVE, EARS
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:21AM CDT
How will medical stocks Bio-Techne, WAVE Life Sciences, and Auris perform this earnings season?
WVE: 34.32 (+0.71), EARS: 1.71 (-0.05), TECH: 108.34 (-1.17)
WAVE Life Sciences (WVE) in Focus: Stock Up 6.1% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 7:35AM CDT
WAVE Life Sciences Ltd. (WVE) was a big mover last session, as the company saw its shares rise over 6% on the day.
WVE: 34.32 (+0.71), ANIP: 66.64 (-0.17)
WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington's Disease
BusinessWire - Tue Jun 21, 6:00AM CDT
--On track to file investigational new drug (IND) application in late 2016
WVE: 34.32 (+0.71)
WAVE Life Sciences to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Wed Jun 01, 6:30AM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference at 3:00 PM Eastern Time on Wednesday, June 8, 2016 in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 16, 3:30PM CDT
--Entered collaboration with Pfizer to develop genetically targeted therapies for the treatment of metabolic diseases
WVE: 34.32 (+0.71)
WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to Address Unmet Need in Duchenne Muscular Dystrophy
BusinessWire - Mon May 09, 7:00AM CDT
--Preclinical data demonstrates 25-fold enhanced exon-skipping efficiency and broader distribution, including to heart and diaphragm, compared to other exon-skipping therapies
WVE: 34.32 (+0.71)
WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases
BusinessWire - Thu May 05, 6:02AM CDT
WAVE Life Sciences Ltd. (NASDAQ:WVE) today announced that it has entered into a research, license and option agreement with Pfizer Inc. (NYSE: PFE) for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE's proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer's hepatic targeting technology for enhanced delivery to the liver.
WVE: 34.32 (+0.71), PFE: 34.26 (+0.11)
WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference
BusinessWire - Fri Apr 29, 6:30PM CDT
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Deutsche Bank 41st Annual Health Care Conference at 3:30 PM EDT on Wednesday, May 4, 2016 in Boston, Mass.
WVE: 34.32 (+0.71), DB: 12.75 (-0.25)
WAVE Life Sciences to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Wed Feb 03, 6:30AM CST
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on advancing potential best-in-class stereopure nucleic acid therapies, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
WVE: 34.32 (+0.71)
WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018
BusinessWire - Fri Jan 29, 6:30AM CST
--Over 20 stereopure antisense, exon skipping, and RNAi programs in early discovery and development across multiple therapeutic areas that have the potential to be best-in-class
WVE: 34.32 (+0.71)
WAVE Life Sciences prices IPO at USD16.00 per share
M2 - Wed Nov 11, 7:29AM CST
Biopharmaceutical company WAVE Life Sciences Ltd (NASDAQ: WVE) announced on Wednesday that it has priced its initial public offering (IPO) at a price to the public of USD16.00 per share for its offering 6,375,000 ordinary shares.
WVE: 34.32 (+0.71)
(0)
(0)